Indicative of ongoing clinical trials are a Phase 2 study with cemiplimab in patients with angiosarcoma and a Phase 1 study of AGEN1181, an Fc-engineered anti-CTLA-4 monoclonal antibody as monotherapy and in combination with AGEN2034 (Balstilimab), an anti-PD-1 monoclonal antibody, in subjects with advanced cancer, including angiosarcoma. The gene discussed is CTLA4; the disease is angiosarcoma.